ClinicalTrials.gg
CompletedNCT04141670Updated Aug 22, 2024Results posted

S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

A Phase 1 interventional study of S48168 in RYR-1 Myopathy, sponsored by Armgo Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Armgo Pharma, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.

Enrollment
57th of 66
7 · median 38
Started
2020
with 2 others
Phase 1
10 of 99
3 open now
Registered
60th of 99
by date

Among the 99 studies in Muscular Diseases with a site in United States, this one is the 57th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2020, is one of 10 in phase 1, and was the 60th registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Muscular Diseases with a site in United States, or all of them as a file.
02

Study summary

This study proposes to test S 48168 (ARM210) in a Phase 1 trial in RYR1-RM patients, specifically. The objectives of this study are to explore the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD)/target engagement (TE) of S 48168 (ARM210), as well as effects on muscle/motor function, and fatigue in RYR1-RM patients. The study population will include adult patients (≥18 years of age) who have demonstrated leaky RyR1 channels that are responsive to S48168 (ARM210) ex vivo.

Read the detailed description

RYR1- related myopathy comprises a group of rare neuromuscular diseases. Affected individuals generally present with delayed motor milestones, muscle weakness, impaired ambulation, and, in severe cases, scoliosis, ophthalmoplegia, and respiratory distress all due to skeletal muscle weakness.

Causative variants in RYR1, which encodes the major calcium (Ca2+) release channel in skeletal muscle, RyR1, exert different effects on the RyR1 channel. They generally disrupt the normal Ca2+ flow between the sarcoplasmic reticulum (SR) and muscle cell cytosol and commonly result in excessive Ca2+ leak into the cytosol. Persistent Ca2+ leaks reduce its availability in the SR that is necessary for excitation-contraction coupling leading to the muscle weakness characteristic of this disease.

This open-label study consists of ten participants, randomized to two dose groups. All participants will have a diagnosis of RYR1-RM. In addition they have a prior muscle biopsy demonstrating a leaky RYR1 channel which responds to S48168 (ARM210) ex vivo. The first group of three participants will receive a low dose of S 48168 (ARM210) daily for 28 days. The second group of seven participants will receive a higher dose for 28 days. The decision to escalate to the higher dose will be made by an independent Data and Safety Monitoring Board (DSMB) after review of safety, tolerability and PK of the low daily dose. Safety and tolerability will be the primary objective in this study. In addition, exploratory objectives will include PK, PD/TE as well as measures of muscle/motor function and fatigue.

03

Conditions studied

  • RYR-1 Myopathy

Browse trials for

Keywords

  • RYR1
  • Myopathy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following conditions to be eligible for enrollment into the study:

  1. (BMI) ≥ 18.0 and ≤ 36.0 kg/m2 at screening.
  2. Confirmed genetic diagnosis of RYR1-RM and supporting clinical phenotype.
  3. Ambulatory. Able to walk ten meters (with or without assistance e.g. with a cane).
  4. Prior muscle with demonstrated leaky RyR1 channel.
  5. Must have a CYP2C8 extensive or intermediate metabolizer genotype.
  6. Daily use of medicines and dietary supplements need to be approved by the PI and Sponsor, or a drug/supplement-dependent prior to inclusion.
  7. For male subjects: is sterile or agrees to use an appropriate method of , including a condom with spermicide, from study drug administration on the first day of dosing until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug administration. No restrictions are required for a vasectomized male subject provided the subject is at least 1-year post-bilateral vasectomy procedure prior to study drug administration on first day of the first dose. A male subject whose vasectomy procedure was performed less than 1 year prior to study drug administration on the first day of dosing must follow the same restrictions as a non-vasectomized male. Appropriate documentation of surgical procedure should be provided.
  8. For male subjects: agrees to not donate sperm from study drug administration on the first day of dosing until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug.
  9. For female subjects of : uses one of the following highly effective birth control methods:

    • Prescribed hormonal oral contraceptives, vaginal ring, or transdermal patch.
    • Intrauterine device (IUD).
    • Intrauterine hormone-releasing system (IUS).
    • Depot/implantable hormone (e.g., Depo-provera®, Implanon).
    • Bilateral tubal occlusion/ligation.
    • Sexual abstinence:
    • Refraining from heterosexual intercourse during the entire period of risk associated with the study requirements.
    • If the participant decides to become sexually active during the study, then one of the highly effective birth control methods must be used.
  10. For female subjects of non childbearing potential; defined by at least 1 of the following criteria:

    • defined as 12 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) serum level > 40mIU/mL. Appropriated documentation of FSH levels is required.
    • Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation of surgical procedure.
    • Has a congenital condition resulting in no uterus.
  11. Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and study procedures (muscle biopsies and PK sampling).
  12. Able to provide written and understands the study procedures in the informed consent form (ICF).

Exclusion criteria

EXCLUSION CRITERIA:

The presence of any of the following conditions will exclude a patient from study enrollment:

  1. Patient is mentally or legally incapacitated at the time of the screening visit or during the conduct of the study.
  2. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose of study drug.
  3. History or presence of or idiosyncratic reaction to the study drug, related compounds, or inactive ingredients.
  4. Positive urine drug or alcohol results at screening.
  5. Positive results at screening for (HIV), surface antigen (HBsAg), or virus (HCV).
  6. Patients with baseline levels three times above the (ULN) or baseline AST levels five times the ULN (isolated elevations of total \<2 X ULN with direct bilirubin below the ULN will be included).
  7. Patients with severe pulmonary dysfunction at screening (Forced Vital Capacity (FVC) \< 50% predicted) or evidence of pulmonary exacerbation. Pulmonary exacerbations refer to an acute worsening of respiratory symptoms that result from a decline in lung function.
  8. Patients with a history of a seizure.
  9. Subject has a history of cancer () Exceptions: (1) Subjects with adequately treated non-melanomatous carcinoma or carcinoma in situ of the cervix may participate in the trial (2) Subjects with other malignancies who have been successfully treated > 10 years prior to the screening where in the judgment of the investigator has revealed no evidence of recurrence from the time of treatment through the time of the screening except those identified at the beginning of the exclusion criterion or (3) Subjects who in the opinion of the investigator are highly unlikely to sustain a recurrence for the duration of the trial.
  10. Patients with uncontrolled diabetes defined as > 7% or diabetic neuropathy.
  11. Estimated \<40 mL/minute at screening, which may be calculated using the Chronic Kidney Disease Epidemiology Collaborative method (), due to reduced muscle mass often seen in RYR1-RM patients.
  12. Patients with a abnormality on their other than hypertensive related, or heart failure ( \<30%) or other clinically significant structural heart disease on echocardiogram.
  13. Patients with a history of myocardial infarction in the last five years, or evidence of congestive heart failure.
  14. Pregnant and breastfeeding women.
  15. Patients who have taken Aspirin, Ibuprofen, or Naproxen within the 3 days prior to the muscle procedure, and/or patients who have taken Plavix (clopidogrel) or Brilinta (ticagrelor) 5 days prior to the muscle biopsy.
  16. Unable to refrain from or anticipates the use of:

    • Any non-approved medicines and/or dietary supplements beginning 14 days prior to the first dose of study drug and throughout the study. Thyroid hormone replacement medication may be permitted if subject has been on same stable dose for the last 3 months prior to the first dose of study drug. Medicines that would contraindicate the skeletal muscle needle biopsy procedure, and therefore would be considered non- approved, include but are not limited systemic anticoagulants or oral direct thrombin inhibitors.
    • Any drugs known to be significant inducers or inhibitors of CYP2C8 enzymes for 28 days prior to the first dose of study drug and throughout the study. Any substrates of breast cancer resistance protein (BCRP).
  17. Is currently taking any drug which raises gastric pH, including proton pump inhibitors or H2 antagonists. Antacids may be used if taken at night.
  18. Donation of blood or significant blood loss within 56 days prior to the first dose of study drug.
  19. Plasma donation within 7 days prior to the first dose of study drug.
  20. Participation in clinical trials for other therapeutic drugs simultaneously or within the 4 weeks prior to the first dose of study drug.
  21. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.
  22. Is an NIH employee who is a subordinate/relative/coworker of a study investigator.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Low dose group

    Experimental: 120 mg S48168 (ARM210; 6 x 20 mg tablets) daily for 29 days

    Drug: S48168

  • Experimental
    High dose group

    Experimental: 200 mg S48168 (ARM210; 10 x 20 mg tablets) daily for 28 days (1 participant) or 29 days (3 participants)

    Drug: S48168

Interventions

  • DrugS48168

    A novel oral small molecule which is designed to repair leaky RYR1 channels

    Also known as: ARM 210

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210)

    Composite safety and tolerability profile of S48168 (ARM210) based on adverse event reporting

    Time frame: 42 days

07

Results

Posted Apr 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneLow Dose GroupHigh Dose Group
Started34
Completed34
Not completed00

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events When Treated With S48168 (ARM210)

Composite safety and tolerability profile of S48168 (ARM210) based on adverse event reporting

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210)
ParticipantsLow Dose GroupHigh Dose Group
Participants with fatal adverse events (all cause mortality)00
Participants with serious adverse events00
Participants with non-serious adverse events33

Adverse events

Collected over Approximately two months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Group0/3 (0%)0/3 (0%)3/3 (100%)
High Dose Group0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLow Dose GroupHigh Dose Group
HeadacheNervous system disorders0/32/4
EosinophiliaBlood and lymphatic system disorders1/30/4
DiarrhoeaGastrointestinal disorders1/30/4
DyspepsiaGastrointestinal disorders1/30/4
Gastrooesophageal reflux diseaseGastrointestinal disorders1/30/4
Skin lacerationInjury, poisoning and procedural complications1/30/4
Blood creatine phosphokinase increasedInvestigations1/30/4
HyperglycaemiaMetabolism and nutrition disorders1/31/4
HyperkalaemiaMetabolism and nutrition disorders1/30/4
ArthralgiaMusculoskeletal and connective tissue disorders1/31/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low Dose GroupHigh Dose GroupTotal
<=18 years000
Between 18 and 65 years347
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose GroupHigh Dose GroupTotal
Female123
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Dose GroupHigh Dose GroupTotal
Hispanic or Latino000
Not Hispanic or Latino347
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose GroupHigh Dose GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White235
More than one race000
Unknown or Not Reported112
Body mass index
Body mass index(kg/m^2)Low Dose GroupHigh Dose GroupTotal
Mean24 ± 531 ± 528 ± 6
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: six months after publication

Access criteria: published results and associated data will be available to academic medical researchers and patient advocacy groups upon request from ARMGO Pharma, INC

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2022, 28 months.

Results were first posted in Apr 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2019
First posted
Oct 28, 2019
StartActual
Aug 25, 2020
Primary completionActual
Dec 30, 2022
CompletionActual
Jul 30, 2023
Results first posted
Apr 19, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04141670
Lead sponsor
Armgo Pharma, Inc.
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Aug 25, 2020
Primary completion
Dec 30, 2022
Completion
Jul 30, 2023
Results posted
Apr 19, 2024
Last update
Aug 22, 2024

Study contacts

Payam Mohassel, M.D.
principal investigator · National Institute of Neurological Disorders and Stroke (NINDS)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surlorian

Start the discussion